ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies

Hitesh
thehealthco.info

ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic agents in red blood cells, and PHARECYDES Pharma, a biotechnology company specializing in precision phage therapy for the treatment of drug-resistant and/or complex bacterial infections, announced today their proposed strategy in combination to create a global player in therapy. phage prolongs and accelerates the development of a portfolio of drug candidates targeting pathogenic bacteria and other possible markers of high unmet medical need.

The proposed transaction aims to leverage ERYTECH’s financial resources and teams to accelerate and expand PHARECYDES’ existing phage development programs, enhancing efforts to promote athletic candidates. bacteriophages and has the potential to expand into new therapeutic modalities by leveraging the advanced technology platforms and capabilities of both companies. Specifically, the combined company’s planned goals for 2023 and 2024 will be:

Expanding the ongoing Phase 2 PhagoDAIR trial in patients with prosthetic joint infections (PPIs) of the knee or hip caused by Staphylococcus aureus (S. aureus), by opening new research centers in Europe, with results expected in the first quarter of 2024;

Expanding the reach of PHARECYDES’ phage therapy clinical portfolio with two additional company-sponsored Phase 2 trials, one in patients with S. aureus endocarditis, is planned. will begin in mid-2023, and a second trial in patients with urinary tract infections complicated by E. coli, is scheduled to launch in Q1 2024. The company plans to open other tests. research centers in the United States for both studies;

Building a research and development strategy based on the foundation and expertise of ERYTECH,

including erythrocyte-derived drug delivery (ERYCAPS) or erythrocyte-derived vesicles (ERYCEV), formulation expertise, and oncology experience to support phage and endolysin therapies in the areas of anti-inflammatory drugs. inflammation – infection such as AMR and beyond (as in food, cosmetics and animal health), or the development of new vectors;

Expanding PHARECYDES’ research portfolio to add two new pathogens in addition to three existing pathogens (S. aureus, P. aeruginosa, E. Coli), is important for developing a comprehensive target portfolio in the fight against drug-resistant bacterial infections; And

Rely on ERYTECH’s presence in the US to facilitate access to US investors as well as clinical and regulatory players for future clinical development.

ERYTECH and PHARECYDES intend to merge their operations and move all teams to ERYTECH’s facility in Lyon, France, where they will benefit from a presentation at a major European infectious disease center.

“This transaction would represent a successful culmination of our efforts to pursue strategic alternatives and a new direction for ERYTECH. After the setback of our Phase 3 trial in pancreatic cancer, we have been looking to leverage our established company structure and capabilities by adding a clinical stage asset in an area of high unmet need. AMR is a major health challenge and phage therapy is a promising approach to target pathogenic bacteria such as S. aureus, E. coli, and P. aeruginosa which in aggregate are responsible for over 800,000 resistant infections annually in the US and Europe. The team at PHERECYDES has made tremendous strides with its programs to date, and we at ERYTECH believe that our capabilities, expertise and assets could significantly complement and add to these efforts and accelerate the path to value creation. We and our board of directors believe the combination of ERYTECH and PHERECYDES would form a company well positioned to be a global leader in phage therapies and provide a much-needed solution to address the increasingly alarming health context caused by antimicrobial-resistant bacteria. We will also explore the opportunity to combine both companies’ know-how and capabilities to broaden to other therapeutic areas of high unmet need. We are excited to begin this new path.”
Gil Beyen, Chief Executive Officer of ERYTECH.
“Our board of directors fully supports this transaction and is convinced that ERYTECH and PHERECYDES will gather critical expertise and capabilities enabling to boost our research programs, as well as a seasoned and very complementary management team, and an international position providing access to US investors and stakeholders. All these assets will also drive and accelerate PHERECYDES clinical development plan with controlled and randomized international trials to demonstrate clinical evidence of phage therapy as a real game changer in the anti-infectious area. With my entire Management team we are eager to start working together with our ERYTECH colleagues.”
Thibaut du Fayet, Chief Executive Officer of PHERECYDES.
Next Post

MetroHealth partners with Rali to share proven best practices for diversity, equity, and inclusion 

Diversity, equity, and inclusion have been embedded in the MetroHealth system’s culture since its inception nearly two centuries ago. These values ​​inform how MetroHealth serves its community and operates as an employer. Now, through a partnership with Rali, an innovative learning and behavior change platform, the hospital system will share […]
thehealthco.info